MOLN vs. VXRT, CRDL, DBVT, KPTI, SCLX, VIGL, OMGA, CRDF, LIFE, and BCAB
Should you be buying Molecular Partners stock or one of its competitors? The main competitors of Molecular Partners include Vaxart (VXRT), Cardiol Therapeutics (CRDL), DBV Technologies (DBVT), Karyopharm Therapeutics (KPTI), Scilex (SCLX), Vigil Neuroscience (VIGL), Omega Therapeutics (OMGA), Cardiff Oncology (CRDF), aTyr Pharma (LIFE), and BioAtla (BCAB). These companies are all part of the "medical" sector.
Molecular Partners (NASDAQ:MOLN) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, community ranking, risk, media sentiment and institutional ownership.
26.6% of Molecular Partners shares are owned by institutional investors. Comparatively, 18.1% of Vaxart shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by company insiders. Comparatively, 3.0% of Vaxart shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Molecular Partners currently has a consensus target price of $4.50, suggesting a potential upside of 26.76%. Vaxart has a consensus target price of $3.00, suggesting a potential upside of 248.72%. Given Vaxart's stronger consensus rating and higher probable upside, analysts plainly believe Vaxart is more favorable than Molecular Partners.
Molecular Partners has a net margin of -885.11% compared to Vaxart's net margin of -1,117.56%. Molecular Partners' return on equity of -31.10% beat Vaxart's return on equity.
In the previous week, Vaxart had 6 more articles in the media than Molecular Partners. MarketBeat recorded 8 mentions for Vaxart and 2 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.93 beat Vaxart's score of 0.31 indicating that Molecular Partners is being referred to more favorably in the media.
Molecular Partners has higher revenue and earnings than Vaxart. Molecular Partners is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.
Vaxart received 298 more outperform votes than Molecular Partners when rated by MarketBeat users. Likewise, 65.47% of users gave Vaxart an outperform vote while only 44.00% of users gave Molecular Partners an outperform vote.
Molecular Partners has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Vaxart has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500.
Summary
Molecular Partners and Vaxart tied by winning 9 of the 18 factors compared between the two stocks.
Get Molecular Partners News Delivered to You Automatically
Sign up to receive the latest news and ratings for MOLN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MOLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Molecular Partners Competitors List
Related Companies and Tools
